On one hand, TNF-α can decrease IL-5 levels and eosinophilia, shifting inflammation from a neutrophil to an eosinophil bias (Fei et al., 2011); however, TNF-α blockade has shown no efficacy in treating anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (Group. This evidence concerns the gene TNF and vasculitis.